OBJECTIVE: 1) Understand that cutaneous scalp and forehead squamous cell carcinomas (scc) are highly aggressive. 2) Understand specific patient and tumor characteristics that are P187 Poster Presentations
OBJECTIVE: 1) Determine the incidence of OSA in HNC patients. 2) Compare this group to patients presenting to the general otolaryngology clinics. METHOD: Obstructive sleep apnea (OSA) is an often underdiagnosed condition that can lead to severe health problems. Studies have shown that head and neck cancer (HNC) patients with OSA have a higher incidence of cardiopulmonary complications postoperatively. An Epworth Sleepiness Score (ESS), a validated tool to screen for obstructive sleep apnea, was completed by patients with HNC and patients presenting to the general otolaryngology clinic. Clinicodemographic data, type of head and neck neoplasm and type of treatment were collated. RESULTS: 34 post-treatment HNC patients and 190 controls completed the ESS. The HNC group was composed of 18 women and 16 men (average age 63.7 ϩ/-16.1), whereas the control group was composed of 100 women and 90 men (average age 51.2 ϩ/-16.6). 47.1% patients in the HNC group and 28.9% in the control group screened positive (pϭ0.046). CONCLUSION: Epworth results demonstrate that patients with HNC have a higher incidence of excessive daytime sleepiness, a surrogate for OSA, when compared to patients presenting for other otolaryngological problems in our ENT clinics.
Human Papillomavirus and Oropharyngeal Cancer in Japan
Satoshi Kano, MD, PhD (presenter); Akihiro Homma, MD, PhD; Nobuhiko Oridate, MD, PhD; Satoshi Fukuda, MD, PhD OBJECTIVE: Oropharyngeal carcinoma prevalence is rising in the Western Europe and the United States. There was a strong association between human papillomavirus (HPV) and oropharyngeal squamous cell carcinoma (SCC). This study provides the first data on HPV in oropharyngeal SCC in Japan.
METHOD:
The presence of HPV was analyzed using multiplex PCR, which was able to detect 16 HPV genotypes (type 6, 11, 16, 18, 30, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 66) with a high degree of reproducibility, from paraffin-embedded tissue of 52 patients diagnosed with oropharyngeal SCC at Hokkaido University Hospital, Japan, between 1998 and 2007. RESULTS: In total 14/52 (27%) were HPV-positive. In 14 HPV-positive patients, 12 patients (86%) were HPV-16-positive, 1 patient (7%) was HPV-18-positive, and 1 patient was HPV-58-positive. HPV-positive patients had significantly better disease-specific (80 vs 55%) (pϽ0.05) survival rates than HPV-negative patients. Compared with patients with HPV-negative tumors, patients with HPV-positive tumors had higher response rates after chemoradiation treatment (disease specific survival 88% vs 43%, pϽ0.05). CONCLUSION: For patients with HNSCC of the oropharynx in Japan, tumor HPV status is strongly associated with chemoradiation response and survival.
Human PLG Antibodies as a HNSCC Therapeutic Benefit
Isaac Dingle, MBA (presenter); James Byrd, MD; Brian Hoel, PhD; M Boyd Gillespie, MSc, MD; Natalie Sutkowski, PhD OBJECTIVE: Placental Growth Factor (PlGF) was recently identified as a novel therapeutic target for inhibiting tumor angiogenesis, and gene expression microarray studies have identified PlGF transcripts in a variety of head and neck squamous cell carcinomas (HNSCC). We have found that PlGF is expressed in human HNSCC cell lines, indicating that PlGF inhibition might have therapeutic benefit in HNSCC. Our objectives were: 1) Isolate and develop immortalized human B-cells expressing IgG antibodies specific for PlGF, 2) verify the existence of PlGF in HNSCC, 3) evaluate the biological activity of the newly developed anti-PlGF antibodies. METHOD: We previously developed methods for isolating human monoclonal antibodies (Hu MAbs) in vitro, in which naive B cells are isolated from tonsillectomy specimens, immortalized with Epstein-Barr virus and induced to undergo class switching. Beginning with multiple tonsil specimens, we used this technique and screened the cell culture supernatants by enzyme linked immunosorbent assay (ELISA) for specific binding to recombinant human PlGF. The B cells producing PlGF specific IgG were then isolated by multiple rounds of limiting dilution cloning. RESULTS: Currently, we have seven B cell lines producing high levels of IgG reactive to PlGF. We have begun preliminary testing of the human antibodies on intracellular PlGF binding in HNSCC tumor specimens, using immunohistochemistry and Western blotting. We are developing functional assays to test the antibodies for inhibition of chemotactic and angiogenic activity. CONCLUSION: This preliminary research sets the stage for determining 1) the role of PlGF in HNSCC and 2) the therapeutic benefit of anti-PLGF therapy.
